These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 6207994)

  • 1. Characterization of two clinical, multiple-drug-resistant isolates of Enterobacter cloacae.
    Traub WH; Häberle R; Bauer D
    Chemotherapy; 1984; 30(5):308-21. PubMed ID: 6207994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined defibrinated human blood and antimicrobial drug activities against Enterobacter cloacae.
    Traub WH; Spohr M
    Chemotherapy; 1983; 29(6):395-400. PubMed ID: 6653172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incomplete cross-resistance of nalidixic and pipemidic acid-resistant variants of Serratia marcescens against ciprofloxacin, enoxacin, and norfloxacin.
    Traub WH
    Chemotherapy; 1985; 31(1):34-9. PubMed ID: 3156026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.
    Chin NX; Neu HC
    Antimicrob Agents Chemother; 1983 Nov; 24(5):754-63. PubMed ID: 6229216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Beta-lactam resistance in aquatic Enterobacter cloacae strains using phenotypic and genotypic criteria].
    Lazăr V; Cernat R; Balotescu C; Cotar A; Coipan E; Cojocaru C
    Bacteriol Virusol Parazitol Epidemiol; 2002; 47(3-4):185-91. PubMed ID: 15085610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory evaluation of enoxacin: comparison with norfloxacin and nalidixic acid.
    Teoh-Chan CH; Cowlishaw A; Eley A; Slater G; Greenwood D
    J Antimicrob Chemother; 1985 Jan; 15(1):45-52. PubMed ID: 3156113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.
    Barry AL; Jones RN
    Antimicrob Agents Chemother; 1984 Jun; 25(6):775-7. PubMed ID: 6234858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Typing of Enterobacter spp. by bacteriocin susceptibility and its use in epidemiological analysis.
    Bauernfeind A; Petermüller C
    J Clin Microbiol; 1984 Jul; 20(1):70-3. PubMed ID: 6746888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacteriocin typing of clinical isolates of Enterobacter cloacae.
    Traub WH; Spohr M; Blech R
    J Clin Microbiol; 1982 Nov; 16(5):885-9. PubMed ID: 7153338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo antibacterial activity of AT-2266.
    Kouno K; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1983 Jul; 24(1):78-84. PubMed ID: 6226242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraphagocytic bactericidal activity of bacterial DNA gyrase inhibitors against Serratia marcescens.
    Traub WH
    Chemotherapy; 1984; 30(6):379-86. PubMed ID: 6097410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enoxacin: in-vitro and animal evaluation as a parenteral and oral agent against hospital bacterial isolates.
    Heifetz CL; Bien PA; Cohen MA; Dombrowski ME; Griffin TJ; Malta TE; Sesnie JC; Shapiro MA; Wold SA
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():29-42. PubMed ID: 3129392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alteration of bacterial DNA structure, gene expression, and plasmid encoded antibiotic resistance following exposure to enoxacin.
    Courtright JB; Turowski DA; Sonstein SA
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():1-18. PubMed ID: 2834313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound.
    Chartrand SA; Scribner RK; Weber AH; Welch DF; Marks MI
    Antimicrob Agents Chemother; 1983 May; 23(5):658-63. PubMed ID: 6223577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotic resistance and conjugative R plasmids in clinical isolates of Enterobacteriaceae in Peninsular Malaysia.
    Koh CL
    Trans R Soc Trop Med Hyg; 1986; 80(1):158-61. PubMed ID: 3726978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ways to overcome cephalosporinase-mediated beta-lactam resistance in Enterobacter cloacae.
    Then RL; Angehrn P
    Chemioterapia; 1985 Feb; 4(1):83-9. PubMed ID: 3872727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotic susceptibility and beta-lactamase production in clinical isolates of Enterobacter spp.
    Lindh E; Dornbusch K; Jalakas K; Forsgren A
    APMIS; 1990 May; 98(5):462-70. PubMed ID: 2162681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of beta-lactamase expression on susceptibility of local isolates of Enterobacter cloacae, Serratia marcescens and Pseudomonas aeruginosa to beta-lactam antibiotics.
    Ramadan MA; Tawfik AF; Shibl AM
    Chemotherapy; 1995; 41(3):193-9. PubMed ID: 7656665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of carbapenemases, extended spectrum β-lactamases and molecular epidemiology of carbapenem-non-susceptible Enterobacter cloacae in a Chinese hospital in Chongqing.
    Dai W; Sun S; Yang P; Huang S; Zhang X; Zhang L
    Infect Genet Evol; 2013 Mar; 14():1-7. PubMed ID: 23220359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phage types, antibiograms and R-plasmids of Klebsiella and Enterobacter isolated from hospital environment and food.
    Horváth J; Lantos J; Fekete J; Marjai E
    Acta Microbiol Hung; 1986; 33(4):285-94. PubMed ID: 3630626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.